Health Catalyst (NASDAQ:HCAT) Issues Earnings Results, Beats Estimates By $0.01 EPS

Posted by on May 11th, 2026

Health Catalyst (NASDAQ:HCAT – Get Free Report) released its earnings results on Monday. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01, FiscalAI reports. The business had revenue of $70.76 million for the quarter, compared to analysts’ expectations of $69.24 million. Health Catalyst had a negative return on equity of 4.30% and a negative net margin of 57.20%.

Health Catalyst Trading Down 9.2%

NASDAQ HCAT traded down $0.14 during trading on Monday, hitting $1.38. 281,362 shares of the company’s stock traded hands, compared to its average volume of 763,214. The stock has a fifty day moving average of $1.37 and a two-hundred day moving average of $2.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.89 and a quick ratio of 1.89. Health Catalyst has a 12-month low of $0.96 and a 12-month high of $4.74. The firm has a market cap of $101.55 million, a P/E ratio of -0.54 and a beta of 1.63.

Institutional Trading of Health Catalyst

Institutional investors have recently added to or reduced their stakes in the business. Focus Partners Wealth purchased a new stake in Health Catalyst during the first quarter valued at about $46,000. nVerses Capital LLC purchased a new stake in shares of Health Catalyst during the fourth quarter worth about $25,000. Cresset Asset Management LLC purchased a new stake in shares of Health Catalyst during the second quarter worth about $39,000. BNP Paribas Financial Markets boosted its holdings in shares of Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after purchasing an additional 6,832 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Health Catalyst by 19.6% during the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after purchasing an additional 4,341 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HCAT has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research note on Friday, March 27th. Stephens reduced their target price on Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating on the stock in a research note on Friday, March 13th. Citigroup reduced their target price on Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, March 13th. Raymond James Financial set a $3.00 target price on Health Catalyst in a research note on Friday, March 13th. Finally, Canaccord Genuity Group cut their price target on shares of Health Catalyst from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.80.

Read Our Latest Stock Report on Health Catalyst

About Health Catalyst

(Get Free Report)

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.

Read More

Earnings History for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.